Lilly's Cyramza meets in biomarker-selected HCC population

Eli Lilly and Co. (NYSE:LLY) said second-line treatment with Cyramza ramucirumab met the primary endpoint of improving overall survival (OS) compared with placebo in the Phase III REACH-2 trial to treat hepatocellular carcinoma in patients with high alpha fetoprotein (AFP) levels.

Lilly plans to initiate regulatory submissions for Cyramza in the biomarker-selected HCC population in mid-2018. The pharma said about half of all advanced HCC patients have elevated AFP levels, defined as ≥400 ng/mL...